Advances in imaging in the postoperative patient with a rising prostate-specific antigen level Journal Article


Authors: Hricak, H.; Schöder, H.; Pucar, D.; Lis, E.; Eberhardt, S. C.; Onyebuchi, C. N.; Scher, H. I.
Article Title: Advances in imaging in the postoperative patient with a rising prostate-specific antigen level
Abstract: Imaging prostate cancer continues to represent a clinical challenge for both primary and recurrent disease. In the evaluation of the persistent/recurrent/metastatic prostate cancer, knowledge of cancer location (local v distant), size, and extent are essential in order to design a treatment, tailored to each patient's needs. There are evidence-based guidelines for the use of imaging in assessing the presence of distant spread of prostate cancer. Radionuclide bone scans and computed tomography (CT), magnetic resonance imaging (MRI), and/or positron emission tomography (PET) supplement clinical and biochemical evaluations (prostate-specific antigen [PSA]) for suspected metastatic disease to bones and lymph nodes. There is no consensus about the use of imaging in the evaluation of local tumor recurrence. The use of ultrasound has been limited to biopsy guidance of the prostatic bed, or percutaneous biopsy of enlarged lymph nodes detected on CT or MRI. The use of MRI is evolving. Recent studies indicate that the use of MRI provides valuable information in the evaluation of local tumor recurrence, and nodal and bony metastases. In a patient post-radiation therapy, the method of combining MRI anatomic information with MR spectroscopic metabolic information is evolving. Another modality offering information about anatomy and metabolism of the local disease is PET/CT. The value of PET/CT at present is controversial, but new studies exploring the role of PET/CT in aggressive prostate cancer are promising. © 2003 Elsevier Inc. All rights reserved.
Keywords: treatment outcome; bone neoplasms; review; cancer localization; cancer recurrence; postoperative period; nonhuman; bone metastasis; postoperative care; nuclear magnetic resonance imaging; positron emission tomography; magnetic resonance imaging; lymph node metastasis; lymphatic metastasis; evidence based medicine; prostate specific antigen; computer assisted tomography; neoplasm recurrence, local; tomography, x-ray computed; practice guideline; prostate cancer; prostate-specific antigen; prostatic neoplasms; capromab pendetide in 111; prostatectomy; echography; fluorodeoxyglucose f 18; nuclear magnetic resonance spectroscopy; physical examination; radioisotope; etidronic acid tc 99m; indium 111; radionuclide imaging; percutaneous biopsy; bone scintiscanning; methionine c 11; tomography, emission-computed; radioimmunodetection; practice guidelines; humans; human; male; priority journal
Journal Title: Seminars in Oncology
Volume: 30
Issue: 5
ISSN: 0093-7754
Publisher: Elsevier Inc.  
Date Published: 2003-10-01
Start Page: 616
End Page: 634
Language: English
DOI: 10.1016/s0093-7754(03)00359-2
PUBMED: 14571410
PROVIDER: scopus
DOI/URL:
Notes: Export Date: 25 September 2014 -- Source: Scopus
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. Eric Lis
    138 Lis
  2. Darko Pucar
    12 Pucar
  3. Heiko Schoder
    545 Schoder
  4. Hedvig Hricak
    421 Hricak
  5. Howard Scher
    1130 Scher
Related MSK Work